Yu Ming-Whei, Wu Wan-Jung, Lin Chih-Lin, Liu Chun-Jen, Peng Wei-Ya, Huang Pin-Yu, Huang Yi-Wen, Hu Jui-Ting, Chang Hung-Chuen, Liou Jyh-Ming
Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
Department of Gastroenterology, Ren-Ai Branch, Taipei City Hospital, Taipei, Taiwan.
Hepatol Res. 2024 Aug 19. doi: 10.1111/hepr.14101.
To examine the dynamic change in hepatic steatosis status during repeated assessments over time, and its potential impact on the risk of developing cardiovascular disease (CVD).
We assessed trajectories of hepatic steatosis and other metabolic disorders in 3134 middle-aged adults undergoing longitudinal assessment of ultrasonography during a pre-baseline period (1993-2009) in a population-based cohort study of liver health. Subsequently, we determined the association of hepatic steatosis trajectories with the incidence of CVD among 2185 CVD-free individuals, followed until 2021. Metabolic risk factors and cardiovascular events (including coronary heart disease and stroke) were determined through medical examination and linkage with nationwide health databases.
We identified three discrete trajectories of hepatic steatosis according to changing pattern over time through group-based trajectory modeling: "stable, non-steatosis" (n = 1298), "intermittent" (n = 921), and "persistent steatosis" (n = 915). During the pre-baseline period, hepatic steatosis trajectories were associated with trajectories of developing diabetes and hypertension, and persistent steatosis (vs. other trajectories) was associated with higher risks and rapidly progressive disease patterns. At a median 13.6 years of follow-up, 629 CVD events occurred. A persistent (vs. non-steatosis: HR 1.44, 95% CI 1.17-1.76), but not intermittent, steatosis pattern predicted the future risk of CVD, after adjustment for age, sex, smoking, and obesity. This association was independent of genetic background, and remained after accounting for pre-baseline body-mass index, other cardiometabolic risk factors, Framingham risk score, medications, and hepatic fibrosis score.
The persistence of hepatic steatosis is associated with trajectories of metabolic disorder development and increased risk of CVD. These data have important implications for practice and further research.
研究随着时间的推移,在多次评估过程中肝脂肪变性状态的动态变化及其对发生心血管疾病(CVD)风险的潜在影响。
在一项基于人群的肝脏健康队列研究的基线前期(1993 - 2009年),我们对3134名接受超声纵向评估的中年成年人的肝脂肪变性及其他代谢紊乱轨迹进行了评估。随后,我们在2185名无CVD的个体中确定了肝脂肪变性轨迹与CVD发病率之间的关联,随访至2021年。通过医学检查以及与全国健康数据库的链接确定代谢危险因素和心血管事件(包括冠心病和中风)。
通过基于组的轨迹建模,根据随时间变化的模式,我们确定了三种不同的肝脂肪变性轨迹:“稳定,非脂肪变性”(n = 1298)、“间歇性”(n = 921)和“持续性脂肪变性”(n = 915)。在基线前期,肝脂肪变性轨迹与糖尿病和高血压的发生轨迹相关,持续性脂肪变性(与其他轨迹相比)与更高风险及快速进展的疾病模式相关。在中位随访13.6年时,发生了629例CVD事件。在调整年龄、性别、吸烟和肥胖因素后,持续性(与非脂肪变性相比:风险比1.44,95%置信区间1.17 - 1.76)而非间歇性脂肪变性模式可预测未来CVD风险。这种关联独立于遗传背景,在考虑基线前期体重指数、其他心脏代谢危险因素、弗雷明汉风险评分、药物治疗和肝纤维化评分后仍然存在。
肝脂肪变性的持续性与代谢紊乱发展轨迹及CVD风险增加相关。这些数据对实践和进一步研究具有重要意义。